Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
OMEGAZEPRIME News
Published on October 23, 2026 • Originally reported by David Cox. OMEGAZEPRIME provides independent news coverage and analysis for our readers. Stay informed with the latest developments.
Moderna and Merck’s personalized mRNA vaccine for melanoma reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a trial.
Published on October 23, 2026 • Originally reported by David Cox. OMEGAZEPRIME provides independent news coverage and analysis for our readers. Stay informed with the latest developments.
OMEGAZEPRIME News — For more stories and analysis, visit omegazeprime.com